Xbrane’s Ranibizumab Marches On With US FDA Filing Imminent
Swedish Firm Reveals Further Phase III Data For Proposed Lucentis Biosimilar
With Samsung Bioepis already holding US and EU approvals for biosimilar ranibizumab, Swedish sponsor Xbrane Biopharma says 12-month Phase III data supports ongoing registration of the Lucentis rival in both regions.
